|
1
|
García de Herreros M, Laguna JC, Padrosa J, Barreto TD, Chicote M, Font C, Grafiá I, Llavata L, Seguí E, Tuca A, Viladot M, Zamora-Martínez C, Fernández-Méndez S, Téllez A, Nicolás JM, Prat A, Castro-Rebollo P, Marco-Hernández J. Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment. Diagnostics (Basel) 2024; 14:730. [PMID: 38611643 PMCID: PMC11011727 DOI: 10.3390/diagnostics14070730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 03/24/2024] [Accepted: 03/27/2024] [Indexed: 04/14/2024] Open
Abstract
BACKGROUND Despite the increasing number of ICU admissions among patients with solid tumours, there is a lack of tools with which to identify patients who may benefit from critical support. We aim to characterize the clinical profile and outcomes of patients with solid malignancies admitted to the ICU. METHODS Retrospective observational study of patients with cancer non-electively admitted to the ICU of the Hospital Clinic of Barcelona (Spain) between January 2019 and December 2019. Data regarding patient and neoplasm characteristics, ICU admission features and outcomes were collected from medical records. RESULTS 97 ICU admissions of 84 patients were analysed. Lung cancer (22.6%) was the most frequent neoplasm. Most of the patients had metastatic disease (79.5%) and were receiving oncological treatment (75%). The main reason for ICU admission was respiratory failure (38%). Intra-ICU and in-hospital mortality rates were 9.4% and 24%, respectively. Mortality rates at 1, 3 and 6 months were 19.6%, 36.1% and 53.6%. Liver metastasis, gastrointestinal cancer, hypoalbuminemia, elevated basal C-reactive protein, ECOG-PS greater than 2 at ICU admission, admission from ward and an APACHE II score over 14 were related to higher mortality. Functional status was severely affected at discharge, and oncological treatment was definitively discontinued in 40% of the patients. CONCLUSION Medium-term mortality and functional deterioration of patients with solid cancers non-electively admitted to the ICU are high. Surrogate markers of cachexia, liver metastasis and poor ECOG-PS at ICU admission are risk factors for mortality.
Collapse
Affiliation(s)
- Marta García de Herreros
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Juan Carlos Laguna
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Joan Padrosa
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Tanny Daniela Barreto
- Radiation Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain;
| | - Manoli Chicote
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
| | - Carme Font
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Ignacio Grafiá
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Lucía Llavata
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
| | - Elia Seguí
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Albert Tuca
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Margarita Viladot
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Carles Zamora-Martínez
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Sara Fernández-Méndez
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Adrián Téllez
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Josep Maria Nicolás
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Aleix Prat
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Translational Genomics and Targeted Therapies in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
| | - Pedro Castro-Rebollo
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| | - Javier Marco-Hernández
- Medical Oncology Department, Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (M.G.d.H.); (J.C.L.); (J.P.); (M.C.); (C.F.); (I.G.); (L.L.); (E.S.); (A.T.); (M.V.); (C.Z.-M.); (A.P.)
- Medical Intensive Care Unit, Internal Medicine Department Hospital Clínic de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain; (S.F.-M.); (A.T.); (J.M.N.); (P.C.-R.)
| |
Collapse
|
|
2
|
Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. Biomedicines 2021; 9:biomedicines9101416. [PMID: 34680533 PMCID: PMC8533530 DOI: 10.3390/biomedicines9101416] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2021] [Revised: 09/27/2021] [Accepted: 10/05/2021] [Indexed: 01/07/2023] Open
Abstract
Background: Respiratory failure requiring mechanical ventilation is the major reason for lung cancer patients being admitted to the intensive care unit (ICU). Though molecular targeted therapies, especially epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), have largely improved the survival of oncogene-driven lung cancer patients, few studies have focused on the performance of TKI in such settings. Materials and Methods: This was a retrospective cohort study enrolling non-small cell lung cancer (NSCLC) patients who harbored sensitizing EGFR mutation and had received EGFR-TKIs as first-line cancer therapy in the ICU with mechanical ventilator use. The primary outcome was the 28-day ICU survival rate, and secondary outcomes were the rate of successful weaning from the ventilator and overall survival. Results: A total of 35 patients were included. The 28-day ICU survival rate was 77%, and the median overall survival was 67 days. Multivariate logistic regression revealed that shock status was associated with a lower 28-day ICU survival rate independently (odds ratio (OR) 0.017, 95% confidence interval (CI), 0.000–0.629, p = 0.027), and that L858R mutation (L858R compared with exon 19 deletion, OR, 0.014, 95% CI 0.000–0.450, p = 0.016) and comorbidities of diabetes mellitus (DM) (OR, 0.032, 95% CI, 0.000–0.416, p = 0.014)) were independently predictive of weaning failure. The successful weaning rate was 43%, and the median of ventilator-dependent duration was 22 days (IQR, 12–29). Conclusions: For EGFR mutant lung cancer patients suffering from respiratory failure and undergoing mechanical ventilation, TKI may still be useful, especially in those with EGFR del19 mutation or without shock and DM comorbidity.
Collapse
|
|
3
|
Outcomes of ICU patients with and without perceptions of excessive care: a comparison between cancer and non-cancer patients. Ann Intensive Care 2021; 11:120. [PMID: 34331626 PMCID: PMC8325749 DOI: 10.1186/s13613-021-00895-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 06/29/2021] [Indexed: 11/23/2022] Open
Abstract
Background Whether Intensive Care Unit (ICU) clinicians display unconscious bias towards cancer patients is unknown. The aim of this study was to compare the outcomes of critically ill patients with and without perceptions of excessive care (PECs) by ICU clinicians in patients with and without cancer. Methods This study is a sub-analysis of the large multicentre DISPROPRICUS study. Clinicians of 56 ICUs in Europe and the United States completed a daily questionnaire about the appropriateness of care during a 28-day period. We compared the cumulative incidence of patients with concordant PECs, treatment limitation decisions (TLDs) and death between patients with uncontrolled and controlled cancer, and patients without cancer. Results Of the 1641 patients, 117 (7.1%) had uncontrolled cancer and 270 (16.4%) had controlled cancer. The cumulative incidence of concordant PECs in patients with uncontrolled and controlled cancer versus patients without cancer was 20.5%, 8.1%, and 9.1% (p < 0.001 and p = 0.62, respectively). In patients with concordant PECs, we found no evidence for a difference in time from admission until death (HR 1.02, 95% CI 0.60–1.72 and HR 0.87, 95% CI 0.49–1.54) and TLDs (HR 0.81, 95% CI 0.33–1.99 and HR 0.70, 95% CI 0.27–1.81) across subgroups. In patients without concordant PECs, we found differences between the time from admission until death (HR 2.23, 95% CI 1.58–3.15 and 1.66, 95% CI 1.28–2.15), without a corresponding increase in time until TLDs (NA, p = 0.3 and 0.7) across subgroups. Conclusions The absence of a difference in time from admission until TLDs and death in patients with concordant PECs makes bias by ICU clinicians towards cancer patients unlikely. However, the differences between the time from admission until death, without a corresponding increase in time until TLDs, suggest prognostic unawareness, uncertainty or optimism in ICU clinicians who did not provide PECs, more specifically in patients with uncontrolled cancer. This study highlights the need to improve intra- and interdisciplinary ethical reflection and subsequent decision-making at the ICU. Supplementary Information The online version contains supplementary material available at 10.1186/s13613-021-00895-5.
Collapse
|
|
4
|
Asdahl PH, Christensen S, Kjærsgaard A, Christiansen CF, Kamper P. One-year mortality among non-surgical patients with hematological malignancies admitted to the intensive care unit: a Danish nationwide population-based cohort study. Intensive Care Med 2020; 46:756-765. [PMID: 32072301 DOI: 10.1007/s00134-019-05918-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Accepted: 12/26/2019] [Indexed: 02/08/2023]
Abstract
PURPOSE Contemporary data on mortality of hematological patients admitted to the intensive care unit (ICU) are missing. In a Danish nationwide set-up, we assessed 30-day and 1-year mortality in this population including impact of age and comorbidity, with non-hematological patients as reference. METHODS This population-based cohort study included all non-surgical patients > 15 years of age admitted to an ICU in Denmark between 2010 and 2015. Data on hematological malignancies were obtained from the Danish Hematological Database, and information on the Charlson Comorbidity Index was obtained from the Danish National Patient Registry. Thirty-day and 1-year mortality was estimated using the Kaplan-Meier method. We used Cox proportional hazards regression to estimate hazard ratios. RESULTS We included 2122 ICU patients with a hematological malignancy and 88,951 non-hematological ICU patients. The 30-day mortality was 44% (95% confidence interval: 42-47%) among hematological patients and 27% (27-27%) among non-hematological patients. Similarly, 1-year mortality was 66% (64-68%) and 37% (37-37%), respectively. The corresponding hazard ratio with adjustment for age, sex, and comorbidity was 1.62 (1.54-1.71). Excess mortality was observed in all subgroups of age or of comorbidity. For example, the 1-year mortality for patients with Charlson Comorbidity Index Score > 3: 70% (66-74%) among hematological patients and 62% (61-63%) among non-hematological patients. CONCLUSION ICU patients with hematological malignancy had higher mortality than other ICU patients. However, one third of critically ill patients with a hematological malignancy is alive 1 year after ICU admission.
Collapse
Affiliation(s)
- Peter H Asdahl
- Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200, Aarhus, Denmark.
| | - Steffen Christensen
- Intensive Care Unit, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200, Aarhus, Denmark
| | - Anders Kjærsgaard
- Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark
| | - Christian F Christiansen
- Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark
| | - Peter Kamper
- Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200, Aarhus, Denmark
| |
Collapse
|
|
5
|
Darmon M, Bourmaud A, Georges Q, Soares M, Jeon K, Oeyen S, Rhee CK, Gruber P, Ostermann M, Hill QA, Depuydt P, Ferra C, Toffart AC, Schellongowski P, Müller A, Lemiale V, Mokart D, Azoulay E. Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. Intensive Care Med 2019; 45:977-987. [PMID: 31143998 DOI: 10.1007/s00134-019-05653-7] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Accepted: 05/20/2019] [Indexed: 11/24/2022]
Abstract
PURPOSE The number of averted deaths due to therapeutic advances in oncology and hematology is substantial and increasing. Survival of critically ill cancer patients has also improved during the last 2 decades. However, these data stem predominantly from unadjusted analyses. The aim of this study was to assess the impact of ICU admission year on short-term survival of critically ill cancer patients, with special attention on those with neutropenia. METHODS Systematic review and meta-analysis of individual data according to the guidelines of meta-analysis of observational studies in epidemiology. DATASOURCE Pubmed and Cochrane databases. ELIGIBILITY CRITERIA Adult studies published in English between May 2005 and May 2015. RESULTS Overall, 7354 patients were included among whom 1666 presented with neutropenia at ICU admission. Median ICU admission year was 2007 (IQR 2004-2010; range 1994-2012) and median number of admissions per year was 693 (IQR 450-1007). Overall mortality was 47.7%. ICU admission year was associated with a progressive decrease in hospital mortality (OR per year 0.94; 95% CI 0.93-0.95). After adjustment for confounders, year of ICU admission was independently associated with hospital mortality (OR for hospital mortality per year: 0.96; 95% CI 0.95-0.97). The association was also seen in patients with neutropenia but not in allogeneic stem cell transplant recipients. CONCLUSION After adjustment for patient characteristics, severity of illness and clustering, hospital mortality decreased steadily over time in critically ill oncology and hematology patients except for allogeneic stem cell transplant recipients.
Collapse
Affiliation(s)
- Michaël Darmon
- Medical ICU, Saint-Louis University Hospital, AP-HP, Paris, France. .,Faculté de Médecine, Université Paris-Diderot, Sorbonne-Paris-Cité, Paris, France. .,ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistic Sorbonne Paris Cité, CRESS), INSERM, Paris, France.
| | - Aurélie Bourmaud
- Faculté de Médecine, Université Paris-Diderot, Sorbonne-Paris-Cité, Paris, France.,Public Health Department, Robert Debré University Hospital, AP-HP, Paris, France.,UMRS 1123, Clinical Epidemiology and Economic Evaluation Applied to Vulnerable Populations (Epidémiologie Clinique et Évaluation Économique appliquée aux Populations Vulnérables [ECEVE]), Paris Diderot University, Paris, France
| | - Quentin Georges
- Medical-Surgical ICU, Saint-Etienne University Hospital, Saint-Étienne, France
| | - Marcio Soares
- Department of Critical Care and Graduate Program in Translational Medicine, D'Or Institute for Research and Education, Rio de Janeiro, Brazil
| | - Kyeongman Jeon
- Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Sandra Oeyen
- Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium
| | - Chin Kook Rhee
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Pascale Gruber
- Department of Critical Care, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
| | - Marlies Ostermann
- Department of Critical Care and Nephrology, King's College London, Guy's and St Thomas' NHS Foundation Hospital, London, UK
| | - Quentin A Hill
- Department of Haematology, Leeds Teaching Hospitals, Leeds, UK
| | - Pieter Depuydt
- Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium
| | - Christelle Ferra
- Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Anne-Claire Toffart
- Thoracic Oncology Unit, Grenoble Alpes University Hospital, Grenoble, France
| | - Peter Schellongowski
- Department of Medicine I, Intensive Care Unit 13i2, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Alice Müller
- Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Porto Alegre, Brazil
| | - Virginie Lemiale
- Medical ICU, Saint-Louis University Hospital, AP-HP, Paris, France
| | - Djamel Mokart
- Anesthesiology and Intensive Care Unit, Institut Paoli Calmette, Marseille, France
| | - Elie Azoulay
- Medical ICU, Saint-Louis University Hospital, AP-HP, Paris, France.,Faculté de Médecine, Université Paris-Diderot, Sorbonne-Paris-Cité, Paris, France.,ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistic Sorbonne Paris Cité, CRESS), INSERM, Paris, France
| |
Collapse
|
|
6
|
Dumas G, Biard L, Givel C, Amorim S, Zafrani L, Lemiale V, Mariotte E, Azoulay E, Thiéblemont C, Canet E. Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. Ann Hematol 2018; 98:195-203. [PMID: 30218163 DOI: 10.1007/s00277-018-3496-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Accepted: 09/06/2018] [Indexed: 01/31/2023]
Abstract
T cell non-Hodgkin lymphomas (T-NHLs) are aggressive malignancies which have a high risk of life-threatening complications. However, their prognosis in the intensive care unit (ICU) setting has not yet been assessed. We conducted a study including 87 ICU patients either with newly diagnosed T-NHLs or those undergoing first-line therapy admitted between January 1, 2000, and December 31, 2014. The primary subtypes were peripheral T cell lymphoma (PTCL) (n = 41, 47%), anaplastic large-cell lymphoma (ALCL) (n = 13, 15%), and adult T-leukaemia/lymphoma (ATLL) (n = 11, 13%). Six in every ten patients had malignancy-related complications (haemophagocytic syndrome 37%, tumour lysis syndrome 18% and hypercalcaemia 9%), while infections accounted for one quarter of ICU admissions. Nine fungal infections were documented, including six invasive aspergillosis. Urgent chemotherapy was started in the ICU in 59% of the patients, and urgent surgery was required in 13%. ICU and day-90 mortality were 22% and 41%, respectively. Multivariate analysis showed that SOFA score at day 1, age, sepsis and haemophagocytic syndrome were independent predictors of day-90 mortality. Compared to 66 ICU-matched controls with non-Hodgkin B cell lymphomas, patients with T-NHLs had a similar ICU survival. Overall survival rates of patients with T cell NHLs and B cell NHLs were 20% and 46%, respectively (hazard ratio for death associated with T cell NHLs 2.00 [1.12-3.58]). Patients with T cell NHLs had a very poor long-term outcome. Although the high rate of short-term survival suggests that an ICU trial is a reasonable option for patients newly diagnosed for the malignancy, extended stay in the ICU or further readmission should be considered only for highly selected patients who respond to the haematological treatment.
Collapse
Affiliation(s)
- Guillaume Dumas
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France.
| | - Lucie Biard
- Biostatistics Department, AP-HP, Saint-Louis University Hospital, Paris, France
| | - Claire Givel
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France
| | - Sandy Amorim
- Hemato-Oncology Department, Saint-Louis University Hospital, Paris, France
| | - Lara Zafrani
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, Paris, France
| | - Virginie Lemiale
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France
| | - Eric Mariotte
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France
| | - Elie Azoulay
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, Paris, France
| | - Catherine Thiéblemont
- Hemato-Oncology Department, Saint-Louis University Hospital, Paris, France.,Paris Diderot University, Sorbonne Paris Cité, Paris, France
| | - Emmanuel Canet
- Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France
| |
Collapse
|
|
7
|
De Jong A, Calvet L, Lemiale V, Demoule A, Mokart D, Darmon M, Jaber S, Azoulay E. The challenge of avoiding intubation in immunocompromised patients with acute respiratory failure. Expert Rev Respir Med 2018; 12:867-880. [PMID: 30101630 DOI: 10.1080/17476348.2018.1511430] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
INTRODUCTION A growing number of immunocompromised (IC) patients with acute hypoxemic respiratory failure (ARF) is admitted to the intensive care unit (ICU) worldwide. Areas covered: This review provides an overview of the current knowledge of the ways to prevent intubation in IC patients with ARF. Expert commentary: Striking differences oppose ARF incidence, characteristics, etiologies and management between IC and non-IC patients. Survival benefits have been reported with early admission to ICU in IC patients. Then, while managing hypoxemia and associated organ dysfunction, the identification of the cause of ARF will be guided by a rigorous clinical assessment at the bedside, further assisted by an invasive or noninvasive diagnostic strategy based on clinical probability for each etiology. Finally, the initial respiratory support aims to avoid mechanical ventilation for the many yet recognizing those patients for whom delaying intubation expose them to suboptimal management. We advocate for not using noninvasive ventilation (NIV) in this setting. A proper evaluation of High-flow nasal cannula oxygen (HFNC) is required in IC patients as to demonstrate its superiority compared to standard oxygen therapy. Day-to-day decisions must strive to avoid delayed intubation, and make every effort to identify ARF etiology.
Collapse
Affiliation(s)
- Audrey De Jong
- a Medical Intensive Care Unit , University of Paris-Diderot, Saint Louis Hospital , Paris , France.,b Anesthesiology and Intensive Care; Anesthesia and Critical Care Department B , Saint Eloi Teaching Hospital, PhyMedExp, University of Montpellier , Montpellier , France
| | - Laure Calvet
- a Medical Intensive Care Unit , University of Paris-Diderot, Saint Louis Hospital , Paris , France
| | - Virginie Lemiale
- a Medical Intensive Care Unit , University of Paris-Diderot, Saint Louis Hospital , Paris , France
| | - Alexandre Demoule
- c Service de Pneumologie et Réanimation Médicale , Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, INSERM et Université Pierre et Marie Curie , Paris , France
| | - Djamel Mokart
- d Réanimation Polyvalente et Département d'Anesthésie et de Réanimation , Institut Paoli-Calmettes , Marseille , France
| | - Michael Darmon
- a Medical Intensive Care Unit , University of Paris-Diderot, Saint Louis Hospital , Paris , France.,e ECSTRA Team, and Clinical Epidemiology , UMR 1153 (Center of Epidemiology and Biostatistics, Sorbonne Paris Cité, CRESS), INSERM, Paris Diderot Sorbonne University , Paris , France
| | - Samir Jaber
- b Anesthesiology and Intensive Care; Anesthesia and Critical Care Department B , Saint Eloi Teaching Hospital, PhyMedExp, University of Montpellier , Montpellier , France
| | - Elie Azoulay
- a Medical Intensive Care Unit , University of Paris-Diderot, Saint Louis Hospital , Paris , France.,e ECSTRA Team, and Clinical Epidemiology , UMR 1153 (Center of Epidemiology and Biostatistics, Sorbonne Paris Cité, CRESS), INSERM, Paris Diderot Sorbonne University , Paris , France
| |
Collapse
|
|
8
|
Cortegiani A, Madotto F, Gregoretti C, Bellani G, Laffey JG, Pham T, Van Haren F, Giarratano A, Antonelli M, Pesenti A, Grasselli G. Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2018; 22:157. [PMID: 29895331 PMCID: PMC5998562 DOI: 10.1186/s13054-018-2079-9] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Accepted: 05/22/2018] [Indexed: 12/15/2022]
Abstract
Background The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. Conclusions Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge. Trial registration ClinicalTrials.gov, NCT02010073. Registered on 12 December 2013. Electronic supplementary material The online version of this article (10.1186/s13054-018-2079-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Andrea Cortegiani
- Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Via del vespro 129, 90127, Palermo, Italy.
| | - Fabiana Madotto
- Research Center on Public Health, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
| | - Cesare Gregoretti
- Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Via del vespro 129, 90127, Palermo, Italy
| | - Giacomo Bellani
- School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.,Department of Emergency and Intensive Care, San Gerardo Hospital, Monza, Italy
| | - John G Laffey
- Anesthesia, School of Medicine, National University of Ireland, Galway, Ireland.,Interdepartemental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.,Keenan Research Center for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - Tai Pham
- Interdepartemental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.,Keenan Research Center for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
| | - Frank Van Haren
- College of Medicine, Biology and Environment, Australian National University, Canberra, Australia.,Intensive Care Unit, Canberra Hospital, Canberra, Australia
| | - Antonino Giarratano
- Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Via del vespro 129, 90127, Palermo, Italy
| | - Massimo Antonelli
- Department of Anesthesiology and Intensive Care, Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| | - Antonio Pesenti
- Department of Anesthesiology, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - Giacomo Grasselli
- Department of Anesthesiology, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | |
Collapse
|
|
9
|
Carmona-Bayonas A, Gordo F, Beato C, Castaño Pérez J, Jiménez-Fonseca P, Virizuela Echaburu J, Garnacho-Montero J. Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC. Med Intensiva 2018. [PMID: 29519710 DOI: 10.1016/j.medin.2018.01.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Cancer patients are a vulnerable group exposed to numerous and serious risks beyond cancer itself. In recent years, the prognosis of these individuals has improved substantially thanks to several advances such as immunotherapy, targeted molecular therapies, surgical techniques, or developments in support treatment. This coincides with the prolonged survival of oncological patients admitted to the ICU due to critical complications, and under the supervision of intensivists. The time has therefore come to revisit the intensive care support of these patients, which poses new professional as well as organizational challenges. An agreement was signed in 2017 between the SEOM and SEMICYUC with the aim of improving the quality of care of cancer patients with critical complications. The initiative seeks to aid in decision-making, standardize criteria, decrease subjectivity, generate channels of communication, and delve deeper into the ethical and scientific aspects of these situations. This document sets forth the most important reasons that have led us to undertake this initiative.
Collapse
Affiliation(s)
- A Carmona-Bayonas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB), UMU, Murcia, Spain
| | - F Gordo
- Servicio de Medicina Intensiva, Hospital Universitario del Henares (Coslada-Madrid), Grupo de investigación en patología crítica, Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain
| | - C Beato
- Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain
| | - J Castaño Pérez
- Intensive Care Department, Virgen de las Nieves University Hospital, Granada, Spain
| | - P Jiménez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - J Virizuela Echaburu
- Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain
| | - J Garnacho-Montero
- Intensive Care Clinical Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain.
| |
Collapse
|
|
10
|
Koutsoukou A. Admission of critically ill patients with cancer to the ICU: many uncertainties remain. ESMO Open 2017; 2:e000105. [PMID: 29259818 PMCID: PMC5652547 DOI: 10.1136/esmoopen-2016-000105] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Revised: 10/21/2016] [Accepted: 10/24/2016] [Indexed: 12/14/2022] Open
Affiliation(s)
- Antonia Koutsoukou
- ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens Medical School, 'Sotiria' Hospital, Athens, Greece
| |
Collapse
|
|
11
|
Azoulay E, Schellongowski P, Darmon M, Bauer PR, Benoit D, Depuydt P, Divatia JV, Lemiale V, van Vliet M, Meert AP, Mokart D, Pastores SM, Perner A, Pène F, Pickkers P, Puxty KA, Vincent F, Salluh J, Soubani AO, Antonelli M, Staudinger T, von Bergwelt-Baildon M, Soares M. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med 2017; 43:1366-1382. [PMID: 28725926 DOI: 10.1007/s00134-017-4884-z] [Citation(s) in RCA: 94] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Accepted: 07/08/2017] [Indexed: 12/13/2022]
Abstract
Over the coming years, accelerating progress against cancer will be associated with an increased number of patients who require life-sustaining therapies for infectious or toxic chemotherapy-related events. Major changes include increased number of cancer patients admitted to the ICU with full-code status or for time-limited trials, increased survival and quality of life in ICU survivors, changing prognostic factors, early ICU admission for optimal monitoring, and use of noninvasive diagnostic and therapeutic strategies. In this review, experts in the management of critically ill cancer patients highlight recent changes in the use and the results of intensive care in patients with malignancies. They seek to put forward a standard of care for the management of these patients and highlight important updates that are required to care for them. The research agenda they suggest includes important studies to be conducted in the next few years to increase our understanding of organ dysfunction in this population and to improve our ability to appropriately use life-saving therapies or select new therapeutic approaches that are likely to improve outcomes. This review aims to provide more guidance for the daily management of patients with cancer, in whom outcomes are constantly improving, as is our global ability to fight against what is becoming the leading cause of mortality in industrialized and non-industrialized countries.
Collapse
Affiliation(s)
- Elie Azoulay
- ECSTRA Team, and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics, Sorbonne Paris Cité, CRESS), INSERM, Paris Diderot Sorbonne University, Paris, France. .,Medical Intensive Care Unit, Hôpital Saint-Louis, Paris, France.
| | | | - Michael Darmon
- Saint-Etienne University Hospital, Saint-Etienne, France
| | | | | | | | | | | | | | | | | | | | | | | | - Peter Pickkers
- Radboud University Medical Center, Nijmegen, The Netherlands
| | | | | | - Jorge Salluh
- Instituto de Ensino e Perquisa da Santa Casa de Belo Horizonte, Rio de Janeiro, Brazil
| | | | | | | | | | - Marcio Soares
- Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
| |
Collapse
|
|
12
|
High-Flow Nasal Cannula Oxygenation in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. Crit Care Med 2017; 45:e274-e280. [PMID: 27655324 DOI: 10.1097/ccm.0000000000002085] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE In immunocompromised patients with acute respiratory failure, invasive mechanical ventilation remains associated with high mortality. Choosing the adequate oxygenation strategy is of the utmost importance in that setting. High-flow nasal oxygen has recently shown survival benefits in unselected patients with acute respiratory failure. The objective was to assess outcomes of immunocompromised patients with hypoxemic acute respiratory failure treated with high-flow nasal oxygen. DESIGN We performed a post hoc analysis of a randomized controlled trial of noninvasive ventilation in critically ill immunocompromised patients with hypoxemic acute respiratory failure. SETTING Twenty-nine ICUs in France and Belgium. PATIENTS Critically ill immunocompromised patients with hypoxemic acute respiratory failure. INTERVENTION A propensity score-based approach was used to assess the impact of high-flow nasal oxygen compared with standard oxygen on day 28 mortality. MEASUREMENTS AND MAIN RESULTS Among 374 patients included in the study, 353 met inclusion criteria. Underlying disease included mostly malignancies (n = 296; 84%). Acute respiratory failure etiologies were mostly pneumonia (n = 157; 44.4%) or opportunistic infection (n = 76; 21.5%). Noninvasive ventilation was administered to 180 patients (51%). Invasive mechanical ventilation was ultimately needed in 142 patients (40.2%). Day 28 mortality was 22.6% (80 deaths). Throughout the ICU stay, 127 patients (36%) received high-flow nasal oxygen whereas 226 patients received standard oxygen. Ninety patients in each group (high-flow nasal oxygen or standard oxygen) were matched according to the propensity score, including 91 of 180 (51%) who received noninvasive ventilation. High-flow nasal oxygen was neither associated with a lower intubation rate (hazard ratio, 0.42; 95% CI, 0.11-1.61; p = 0.2) nor day 28 mortality (hazard ratio, 0.80; 95% CI, 0.45-1.42; p = 0.45). CONCLUSIONS In immunocompromised patients with hypoxemic acute respiratory failure, high-flow nasal oxygen when compared with standard oxygen did not reduce intubation or survival rates. However, these results could be due to low statistical power or unknown confounders associated with the subgroup analysis. A randomized trial is needed.
Collapse
|
|
13
|
Abstract
Advances in cancer treatment and patient survival are associated with increasing number of these patients requiring intensive care. Over the last 2 decades, there has been a steady improvement in the outcomes of critically ill patients with cancer. This review provides data on the use of the intensive care unit (ICU) and short and long-term outcomes of critically ill patients with cancer, the ICU system practices that influence patients outcomes, and the role of the different clinical variables in predicting the prognosis of these patients.
Collapse
Affiliation(s)
- Ayman O Soubani
- Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, 3990 John R- 3 Hudson, Detroit, MI 48201, USA.
| |
Collapse
|
|
14
|
Mokart D, Penalver M, Chow-Chine L, Ewald J, Sannini A, Brun JP, Bisbal M, Lelong B, Delpero JR, Faucher M, Turrini O. Surgical treatment of acute abdominal complications in hematology patients: outcomes and prognostic factors. Leuk Lymphoma 2017; 58:2395-2402. [DOI: 10.1080/10428194.2017.1296145] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Djamel Mokart
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Marion Penalver
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Laurent Chow-Chine
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Jacques Ewald
- Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France
| | - Antoine Sannini
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Jean Paul Brun
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Magali Bisbal
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Bernard Lelong
- Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France
| | - Jean Robert Delpero
- Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France
| | - Marion Faucher
- Réanimation Polyvalente et Département d’Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France
| | - Olivier Turrini
- Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
|
15
|
Shimabukuro-Vornhagen A, Böll B, Kochanek M, Azoulay É, von Bergwelt-Baildon MS. Critical care of patients with cancer. CA Cancer J Clin 2016; 66:496-517. [PMID: 27348695 DOI: 10.3322/caac.21351] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Answer questions and earn CME/CNE The increasing prevalence of patients living with cancer in conjunction with the rapid progress in cancer therapy will lead to a growing number of patients with cancer who will require intensive care treatment. Fortunately, the development of more effective oncologic therapies, advances in critical care, and improvements in patient selection have led to an increased survival of critically ill patients with cancer. As a consequence, critical care has become an important cornerstone in the continuum of modern cancer care. Although, in many aspects, critical care for patients with cancer does not differ from intensive care for other seriously ill patients, there are several challenging issues that are unique to this patient population and require special knowledge and skills. The optimal management of critically ill patients with cancer necessitates expertise in oncology, critical care, and palliative medicine. Cancer specialists therefore have to be familiar with key principles of intensive care for critically ill patients with cancer. This review provides an overview of the state-of-the-art in the individualized management of critically ill patients with cancer. CA Cancer J Clin 2016;66:496-517. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Alexander Shimabukuro-Vornhagen
- Consultant, Medical Intensive Care Program, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
- Member, Cologne-Bonn Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
- Founding Member, Intensive Care in Hemato-Oncologic Patients (iCHOP), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Boris Böll
- Member, Cologne-Bonn Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
- Founding Member, Intensive Care in Hemato-Oncologic Patients (iCHOP), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
- Head of Medical Intensive Care Program, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Matthias Kochanek
- Member, Cologne-Bonn Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
- Founding Member, Intensive Care in Hemato-Oncologic Patients (iCHOP), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
- Program Director, Medical Intensive Care Program, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | - Éli Azoulay
- Director, Medical Intensive Care Unit, St. Louis Hospital, Paris, France
- Professor of Medicine, Teaching and Research Unit, Department of Medicine, Paris Diderot University, Paris, France
- Chair, Study Group for Respiratory Intensive Care in Malignancies, St. Louis Hospital, Paris, France
| | - Michael S von Bergwelt-Baildon
- Founding Member, Intensive Care in Hemato-Oncologic Patients (iCHOP), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
- Program Director, Medical Intensive Care Program, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
- Professor, Cologne-Bonn Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
|
16
|
Chien CR, Chen HJ. Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit. J Thorac Dis 2016; 8:E1455-E1461. [PMID: 28066630 DOI: 10.21037/jtd.2016.11.110] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Novel targeted therapy for patients with non-small-cell lung cancer (NSCLC) and oncogenic mutations along with poor performance status (PS) sometimes evokes a "Lazarus" response. Moreover, for critically ill patients with NSCLC and respiratory failure requiring mechanical ventilation (MV) in the intensive care unit (ICU), only a few case reports have demonstrated positive outcomes with targeted therapy. This perspective review describes in detail the most recently published data in order to highlight the findings and the main pitfalls of targeted therapy for patients with NSCLC in the ICU.
Collapse
Affiliation(s)
- Chun-Ru Chien
- Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan;; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
| | - Hung-Jen Chen
- Division of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan;; Department of Respiratory Therapy, China Medical University, Taichung, Taiwan
| |
Collapse
|
|
17
|
Contejean A, Lemiale V, Resche-Rigon M, Mokart D, Pène F, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Rabbat A, Perez P, Meert AP, Benoit D, Hamidfar R, Darmon M, Jourdain M, Renault A, Schlemmer B, Azoulay E. Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologique (Grrr-OH) study. Ann Intensive Care 2016; 6:102. [PMID: 27783381 PMCID: PMC5080277 DOI: 10.1186/s13613-016-0202-0] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2016] [Accepted: 10/11/2016] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Acute respiratory failure (ARF) is the most frequent complication in patients with hematological malignancies and is associated with high morbidity and mortality. ARF etiologies are numerous, and despite extensive diagnostic workflow, some patients remain with undetermined ARF etiology. METHODS This is a post-hoc study of a prospective multicenter cohort performed on 1011 critically ill hematological patients. Relationship between ARF etiology and hospital mortality was assessed using a multivariable regression model adjusting for confounders. RESULTS This study included 604 patients with ARF. All patients underwent noninvasive diagnostic tests, and a bronchoscopy and bronchoalveolar lavage (BAL) was performed in 155 (25.6%). Definite diagnoses were classified into four exclusive etiological categories: pneumonia (44.4%), non-infectious diagnoses (32.6%), opportunistic infection (10.1%) and undetermined (12.9%), with corresponding hospital mortality rates of 40, 35, 55 and 59%, respectively. Overall hospital mortality was 42%. By multivariable analysis, factors associated with hospital mortality were invasive pulmonary aspergillosis (OR 7.57 (95% CI 3.06-21.62); p < 0.005), use of invasive mechanical ventilation (OR 1.65 (95% CI 1.07-2.55); p = 0.02), a SOFA score >7 (OR 3.32 (95% CI 2.15-5.15); p < 0.005) and an undetermined ARF etiology (OR 2.92 (95% CI 1.71-5.07); p < 0.005). CONCLUSIONS In patients with hematological malignancies and ARF, up to 13% remain with undetermined ARF etiology despite comprehensive diagnostic workup. Undetermined ARF etiology is independently associated with hospital mortality. Studies to guide second-line diagnostic strategies are warranted. ClinicalTrials.Gov NCT01172132.
Collapse
Affiliation(s)
| | | | | | - Djamel Mokart
- Réanimation, Institut Paoli Calmettes, Marseille, France.,Medical Intensive Care Unit, Hôpital Saint-Louis, ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology And Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Université Paris Diderot Sorbonne, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Frédéric Pène
- Réanimation médicale, Hôpital Cochin, APHP, Paris, France
| | - Achille Kouatchet
- Service de Reanimation Médicale et Médecine Hyperbare, CHU Angers, Angers, France
| | - Julien Mayaux
- Service de Pneumologie et Réanimation, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France
| | - François Vincent
- Réanimation polyvalente, Hôpital Avicenne, APHP, Bobigny, France
| | - Martine Nyunga
- Réanimation polyvalente, Hôpital V.Provo, Roubaix, France
| | - Fabrice Bruneel
- Réanimation polyvalente, Hôpital de Versailles, Le Chesnay, France
| | - Antoine Rabbat
- Réanimation médicale, Hôpital Cochin, APHP, Paris, France
| | - Pierre Perez
- Réanimation médicale, Hôpital Brabois, Nancy, France
| | - Anne-Pascale Meert
- Service des Soins Intensifs Medico-Chirurgicaux et Oncologie Thoracique, Institut Jules Bordet, Brussels, Belgium
| | | | | | - Michael Darmon
- Réanimation polyvalente, CHU de Saint-Etienne, Saint-Piest-en-Jarrez, France
| | | | - Anne Renault
- Réanimation et Urgences Médicales, CHU de la Cavale Blanche, Brest, France
| | | | - Elie Azoulay
- Réanimation médicale, Hôpital Saint Louis, APHP, Paris, France. .,Medical Intensive Care Unit, Hôpital Saint-Louis, ECSTRA Team, Biostatistics and Clinical Epidemiology, UMR 1153 (Center of Epidemiology And Biostatistics Sorbonne Paris Cité, CRESS), INSERM, Université Paris Diderot Sorbonne, 1, Avenue Claude Vellefaux, 75010, Paris, France.
| |
Collapse
|
|
18
|
Torres VBL, Vassalo J, Silva UVA, Caruso P, Torelly AP, Silva E, Teles JMM, Knibel M, Rezende E, Netto JJS, Piras C, Azevedo LCP, Bozza FA, Spector N, Salluh JIF, Soares M. Outcomes in Critically Ill Patients with Cancer-Related Complications. PLoS One 2016; 11:e0164537. [PMID: 27764143 PMCID: PMC5072702 DOI: 10.1371/journal.pone.0164537] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Accepted: 09/27/2016] [Indexed: 12/13/2022] Open
Abstract
INTRODUCTION Cancer patients are at risk for severe complications related to the underlying malignancy or its treatment and, therefore, usually require admission to intensive care units (ICU). Here, we evaluated the clinical characteristics and outcomes in this subgroup of patients. MATERIALS AND METHODS Secondary analysis of two prospective cohorts of cancer patients admitted to ICUs. We used multivariable logistic regression to identify variables associated with hospital mortality. RESULTS Out of 2,028 patients, 456 (23%) had cancer-related complications. Compared to those without cancer-related complications, they more frequently had worse performance status (PS) (57% vs 36% with PS≥2), active malignancy (95% vs 58%), need for vasopressors (45% vs 34%), mechanical ventilation (70% vs 51%) and dialysis (12% vs 8%) (P<0.001 for all analyses). ICU (47% vs. 27%) and hospital (63% vs. 38%) mortality rates were also higher in patients with cancer-related complications (P<0.001). Chemo/radiation therapy-induced toxicity (6%), venous thromboembolism (5%), respiratory failure (4%), gastrointestinal involvement (3%) and vena cava syndrome (VCS) (2%) were the most frequent cancer-related complications. In multivariable analysis, the presence of cancer-related complications per se was not associated with mortality [odds ratio (OR) = 1.25 (95% confidence interval, 0.94-1.66), P = 0.131]. However, among the individual cancer-related complications, VCS [OR = 3.79 (1.11-12.92), P = 0.033], gastrointestinal involvement [OR = 3.05 (1.57-5.91), P = <0.001] and respiratory failure [OR = 1.96(1.04-3.71), P = 0.038] were independently associated with in-hospital mortality. CONCLUSIONS The prognostic impact of cancer-related complications was variable. Although some complications were associated with worse outcomes, the presence of an acute cancer-related complication per se should not guide decisions to admit a patient to ICU.
Collapse
Affiliation(s)
- Viviane B. L. Torres
- Postgraduate Program in Internal Medicine, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Juliana Vassalo
- Postgraduate Program in Internal Medicine, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | | | - Pedro Caruso
- ICU, A.C. Camargo Cancer Center, São Paulo, Brazil
| | - André P. Torelly
- Rede Institucional de Pesquisa e Inovação em Medicina Intensiva (RIPIMI), Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil
| | - Eliezer Silva
- ICU, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | | | - Marcos Knibel
- Hospital São Lucas, Travessa Frederico Pamplona 32, Rio de Janeiro, Brazil
| | - Ederlon Rezende
- ICU, Hospital do Servidor Público Estadual, São Paulo, Brazil
| | - José J. S. Netto
- ICU, Instituto Nacional de Câncer, Hospital do Câncer II, Rio de Janeiro, Brazil
| | | | | | - Fernando A. Bozza
- IDOR, D’Or Institute for Research and Education, Rio de Janeiro, Brazil
- National Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil
| | - Nelson Spector
- Postgraduate Program in Internal Medicine, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Jorge I. F. Salluh
- Postgraduate Program in Internal Medicine, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
- IDOR, D’Or Institute for Research and Education, Rio de Janeiro, Brazil
- Postgraduate Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Marcio Soares
- Postgraduate Program in Internal Medicine, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
- IDOR, D’Or Institute for Research and Education, Rio de Janeiro, Brazil
- Postgraduate Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
- * E-mail:
| |
Collapse
|
|
19
|
Fisher R, Dangoisse C, Crichton S, Whiteley C, Camporota L, Beale R, Ostermann M. Short-term and medium-term survival of critically ill patients with solid tumours admitted to the intensive care unit: a retrospective analysis. BMJ Open 2016; 6:e011363. [PMID: 27797987 PMCID: PMC5073479 DOI: 10.1136/bmjopen-2016-011363] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVES Patients with cancer frequently require unplanned admission to the intensive care unit (ICU). Our objectives were to assess hospital and 180-day mortality in patients with a non-haematological malignancy and unplanned ICU admission and to identify which factors present on admission were the best predictors of mortality. DESIGN Retrospective review of all patients with a diagnosis of solid tumours following unplanned admission to the ICU between 1 August 2008 and 31 July 2012. SETTING Single centre tertiary care hospital in London (UK). PARTICIPANTS 300 adult patients with non-haematological solid tumours requiring unplanned admission to the ICU. INTERVENTIONS None. PRIMARY AND SECONDARY OUTCOMES Hospital and 180-day survival. RESULTS 300 patients were admitted to the ICU (median age 66.5 years; 61.7% men). Survival to hospital discharge and 180 days were 69% and 47.8%, respectively. Greater number of failed organ systems on admission was associated with significantly worse hospital survival (p<0.001) but not with 180-day survival (p=0.24). In multivariate analysis, predictors of hospital mortality were the presence of metastases (OR 1.97, 95% CI 1.08 to 3.59), Acute Physiology and Chronic Health Evaluation II (APACHE II) Score (OR 1.07, 95% CI 1.01 to 1.13) and a Glasgow Coma Scale Score <7 on admission to ICU (OR 5.21, 95% CI 1.65 to 16.43). Predictors of worse 180-day survival were the presence of metastases (OR 2.82, 95% CI 1.57 to 5.06), APACHE II Score (OR 1.07, 95% CI 1.01 to 1.13) and sepsis (OR 1.92, 95% CI 1.09 to 3.38). CONCLUSIONS Short-term and medium-term survival in patients with solid tumours admitted to ICU is better than previously reported, suggesting that the presence of cancer alone should not be a barrier to ICU admission.
Collapse
Affiliation(s)
- Richard Fisher
- Department of Critical Care, King's College London, Guy's & St Thomas’ Hospital NHS Foundation Trust, London, UK
- Department of Critical Care, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Carole Dangoisse
- Department of Critical Care, King's College London, Guy's & St Thomas’ Hospital NHS Foundation Trust, London, UK
- Department of Critical Care, King's College Hospital NHS Foundation Trust, London, UK
| | - Siobhan Crichton
- Division of Health and Social Care Research, King's College London, London, UK
| | - Craig Whiteley
- Department of Critical Care, King's College London, Guy's & St Thomas’ Hospital NHS Foundation Trust, London, UK
| | - Luigi Camporota
- Department of Critical Care, King's College London, Guy's & St Thomas’ Hospital NHS Foundation Trust, London, UK
| | - Richard Beale
- Department of Critical Care, King's College London, Guy's & St Thomas’ Hospital NHS Foundation Trust, London, UK
| | - Marlies Ostermann
- Department of Critical Care, King's College London, Guy's & St Thomas’ Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
|
20
|
Abstract
Patients with cancer represent a growing group among actual ICU admissions (up to 20 %). Due to their increased susceptibility to infectious and noninfectious complications related to the underlying cancer itself or its treatment, these patients frequently develop acute kidney injury (AKI). A wide variety of definitions for AKI are still used in the cancer literature, despite existing guidelines on definitions and staging of AKI. Alternative diagnostic investigations such as Cystatin C and urinary biomarkers are discussed briefly. This review summarizes the literature between 2010 and 2015 on epidemiology and prognosis of AKI in this population. Overall, the causes of AKI in the setting of malignancy are similar to those in other clinical settings, including preexisting chronic kidney disease. In addition, nephrotoxicity induced by the anticancer treatments including the more recently introduced targeted therapies is increasingly observed. However, data are sometimes difficult to interpret because they are often presented from the oncological rather than from the nephrological point of view. Because the development of the acute tumor lysis syndrome is one of the major causes of AKI in patients with a high tumor burden or a high cell turnover, the diagnosis, risk factors, and preventive measures of the syndrome will be discussed. Finally, we will briefly discuss renal replacement therapy modalities and the emergence of chronic kidney disease in the growing subgroup of critically ill post-AKI survivors.
Collapse
Affiliation(s)
- Norbert Lameire
- Renal Division, Department of Medicine, University Hospital, 185 De Pintelaan, 9000 Gent, Belgium
| | - Raymond Vanholder
- Renal Division, Department of Medicine, University Hospital, 185 De Pintelaan, 9000 Gent, Belgium
| | - Wim Van Biesen
- Renal Division, Department of Medicine, University Hospital, 185 De Pintelaan, 9000 Gent, Belgium
| | - Dominique Benoit
- Medical Intensive Care Unit, University Hospital, 185 De Pintelaan, 9000 Gent, Belgium
| |
Collapse
|
|
21
|
Soares M, Bozza FA, Azevedo LCP, Silva UVA, Corrêa TD, Colombari F, Torelly AP, Varaschin P, Viana WN, Knibel MF, Damasceno M, Espinoza R, Ferez M, Silveira JG, Lobo SA, Moraes APP, Lima RA, de Carvalho AGR, do Brasil PEAA, Kahn JM, Angus DC, Salluh JIF. Effects of Organizational Characteristics on Outcomes and Resource Use in Patients With Cancer Admitted to Intensive Care Units. J Clin Oncol 2016; 34:3315-24. [PMID: 27432921 DOI: 10.1200/jco.2016.66.9549] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
PURPOSE To investigate the impact of organizational characteristics and processes of care on hospital mortality and resource use in patients with cancer admitted to intensive care units (ICUs). PATIENTS AND METHODS We performed a retrospective cohort study of 9,946 patients with cancer (solid, n = 8,956; hematologic, n = 990) admitted to 70 ICUs (51 located in general hospitals and 19 in cancer centers) during 2013. We retrieved patients' clinical and outcome data from an electronic ICU quality registry. We surveyed ICUs regarding structure, organization, staffing patterns, and processes of care. We used mixed multivariable logistic regression analysis to identify characteristics associated with hospital mortality and efficient resource use in the ICU. RESULTS Median number of patients with cancer per center was 110 (interquartile range, 58 to 154), corresponding to 17.9% of all ICU admissions. ICU and hospital mortality rates were 15.9% and 25.4%, respectively. After adjusting for relevant patient characteristics, presence of clinical pharmacists in the ICU (odds ratio [OR], 0.67; 95% CI, 0.49 to 0.90), number of protocols (OR, 0.92; 95% CI, 0.87 to 0.98), and daily meetings between oncologists and intensivists for care planning (OR, 0.69; 95% CI, 0.52 to 0.91) were associated with lower mortality. Implementation of protocols (OR, 1.52; 95% CI, 1.11 to 2.07) and meetings between oncologists and intensivists (OR, 4.70; 95% CI, 1.15 to 19.22) were also independently associated with more efficient resource use. Neither admission to ICUs in cancer centers compared with general hospitals nor annual case volume had an impact on mortality or resource use. CONCLUSION Organizational aspects, namely the implementation of protocols and presence of clinical pharmacists in the ICU, and close collaboration between oncologists and ICU teams are targets to improve mortality and resource use in critically ill patients with cancer.
Collapse
Affiliation(s)
- Marcio Soares
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA.
| | - Fernando A Bozza
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Luciano C P Azevedo
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Ulysses V A Silva
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Thiago D Corrêa
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Fernando Colombari
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - André P Torelly
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Pedro Varaschin
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - William N Viana
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Marcos F Knibel
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Moyzés Damasceno
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Rodolfo Espinoza
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Marcus Ferez
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Juliana G Silveira
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Suzana A Lobo
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Ana Paula P Moraes
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Ricardo A Lima
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Alexandre G R de Carvalho
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Pedro E A A do Brasil
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Jeremy M Kahn
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Derek C Angus
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Jorge I F Salluh
- Marcio Soares, Fernando A. Bozza, Pedro E.A.A. do Brasil, and Jorge I.F. Salluh, D'Or Institute for Research and Education; Fernando A. Bozza and Pedro E.A.A. do Brasil, Instituto Nacional de Infectologia Evandro Chagas, Instituto Oswaldo Cruz-Fiocruz; Pedro Varaschin, Hospital Pasteur; William N. Viana, Hospital Copa D'Or; Marcos F. Knibel, Hospital São Lucas Copacabana; Rodolfo Espinoza, Hospital do Câncer II-Instituto Nacional de Câncer; Juliana G. Silveira, Hospital Quinta D'Or; Ricardo A. Lima, Hospital Samaritano, Rio de Janeiro; Luciano C.P. Azevedo, Hospital Sírio-Libanês; Thiago D. Corrêa, Hospital Israelita Albert Einstein; Fernando Colombari, Hospital Alemão Oswaldo Cruz, São Paulo; Ulysses V.A. Silva, Fundação Pio XII-Hospital de Câncer de Barretos, Barretos; André P. Torelly, Complexo Hospitalar, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre; Moyzés Damasceno, Complexo Hospitalar de Niterói, Niterói; Marcus Ferez, Hospital São Francisco, Ribeirão Preto; Suzana A. Lobo, Hospital de Base de São José do Rio Preto, São José do Rio Preto; Ana Paula P. Moraes, Hospital de Câncer do Maranhão Dr Tarquinio Lopes Filho; Alexandre G.R. de Carvalho, UDI Hospital, São Luís, Brazil; Jeremy M. Kahn, University of Pittsburgh Graduate School of Public Health; and Jeremy M. Kahn and Derek C. Angus, University of Pittsburgh School of Medicine, Pittsburgh, PA
| |
Collapse
|
|
22
|
Lagier D, Platon L, Chow-Chine L, Sannini A, Bisbal M, Brun JP, Blache JL, Faucher M, Mokart D. Severity of Acute Respiratory Distress Syndrome in haematology patients: long-term impact and early predictive factors. Anaesthesia 2016; 71:1081-90. [PMID: 27418297 DOI: 10.1111/anae.13542] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/01/2016] [Indexed: 12/13/2022]
Abstract
Severe forms of acute respiratory distress syndrome in patients with haematological diseases expose clinicians to specific medical and ethical considerations. We prospectively followed 143 patients with haematological malignancies, and whose lungs were mechanically ventilated for more than 24 h, over a 5-y period. We sought to identify prognostic factors of long-term outcome, and in particular to evaluate the impact of the severity of acute respiratory distress syndrome in these patients. A secondary objective was to identify the early (first 48 h from ICU admission) predictive factors for acute respiratory distress syndrome severity. An evolutive haematological disease (HR 1.71; 95% CI 1.13-2.58), moderate to severe acute respiratory distress syndrome (HR 1.81; 95% CI 1.13-2.69) and need for renal replacement therapy (HR 2.24; 95% CI 1.52-3.31) were associated with long-term mortality. Resolution of neutropaenia during ICU stay (HR 0.63; 95% CI 0.42-0.94) and early microbiological documentation (HR 0.62; 95% CI 0.42-0.91) were associated with survival. The extent of pulmonary infiltration observed on the first chest X-ray and the diagnosis of invasive fungal infection were the most relevant early predictive factors of the severity of acute respiratory distress syndrome.
Collapse
Affiliation(s)
- D Lagier
- Institut Paoli-Calmettes, Marseille, France
| | - L Platon
- Institut Paoli-Calmettes, Marseille, France
| | | | - A Sannini
- Institut Paoli-Calmettes, Marseille, France
| | - M Bisbal
- Institut Paoli-Calmettes, Marseille, France
| | - J-P Brun
- Institut Paoli-Calmettes, Marseille, France
| | - J-L Blache
- Institut Paoli-Calmettes, Marseille, France
| | - M Faucher
- Institut Paoli-Calmettes, Marseille, France
| | - D Mokart
- Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
|
23
|
Torres VBL, Soares M. Patients with hematological malignancies admitted to intensive care units: new challenges for the intensivist. Rev Bras Ter Intensiva 2016; 27:193-5. [PMID: 26465241 PMCID: PMC4592109 DOI: 10.5935/0103-507x.20150040] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
| | - Marcio Soares
- Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BR
| |
Collapse
|
|
24
|
Focus on immunocompromised patients. Intensive Care Med 2016; 42:463-465. [PMID: 26820881 DOI: 10.1007/s00134-016-4224-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Accepted: 01/10/2016] [Indexed: 01/21/2023]
|
|
25
|
Lemiale V, Mokart D, Mayaux J, Lambert J, Rabbat A, Demoule A, Azoulay E. The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial. CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2015; 19:380. [PMID: 26521922 PMCID: PMC4629403 DOI: 10.1186/s13054-015-1097-0] [Citation(s) in RCA: 90] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 10/10/2015] [Indexed: 12/13/2022]
Abstract
Introduction In immunocompromised patients, acute respiratory failure (ARF) is associated with high mortality, particularly when invasive mechanical ventilation (IMV) is required. In patients with severe hypoxemia, high-flow nasal oxygen (HFNO) therapy has been used as an alternative to delivery of oxygen via a Venturi mask. Our objective in the present study was to compare HFNO and Venturi mask oxygen in immunocompromised patients with ARF. Methods We conducted a multicenter, parallel-group randomized controlled trial in four intensive care units. Inclusion criteria were hypoxemic ARF and immunosuppression, defined as at least one of the following: solid or hematological malignancy, steroid or other immunosuppressant drug therapy, and HIV infection. Exclusion criteria were hypercapnia, previous IMV, and immediate need for IMV or noninvasive ventilation (NIV). Patients were randomized to 2 h of HFNO or Venturi mask oxygen. Results The primary endpoint was a need for IMV or NIV during the 2-h oxygen therapy period. Secondary endpoints were comfort, dyspnea, and thirst, as assessed hourly using a 0–10 visual analogue scale. We randomized 100 consecutive patients, including 84 with malignancies, to HFNO (n = 52) or Venturi mask oxygen (n = 48). During the 2-h study treatment period, 12 patients required IMV or NIV, and we found no significant difference between the two groups (15 % with HFNO and 8 % with the Venturi mask, P = 0.36). None of the secondary endpoints differed significantly between the two groups. Conclusions In immunocompromised patients with hypoxemic ARF, a 2-h trial with HFNO improved neither mechanical ventilatory assistance nor patient comfort compared with oxygen delivered via a Venturi mask. However, the study was underpowered because of the low event rate and the one-sided hypothesis. Trial registration ClinicalTrials.gov identifier: NCT02424773. Registered 20 April 2015.
Collapse
Affiliation(s)
- Virginie Lemiale
- Medical ICU, Saint Louis Teaching Hospital, AP-HP, 1 avenue Claude Vellefaux, 75010, Paris, France.
| | - Djamel Mokart
- Medical-Surgical ICU, Institut Paoli Calmettes, 13000, Marseilles, France.
| | - Julien Mayaux
- Biostatistics Department, Saint Louis Teaching Hospital, AP-HP, Paris, France.
| | - Jérôme Lambert
- Respiratory ICU, Pitié Salpétrière Teaching Hospital, AP-HP, Paris, France.
| | - Antoine Rabbat
- Respiratory ICU, Cochin Teaching Hospital, AP-HP, Paris, France.
| | - Alexandre Demoule
- Biostatistics Department, Saint Louis Teaching Hospital, AP-HP, Paris, France.
| | - Elie Azoulay
- Medical ICU, Saint Louis Teaching Hospital, AP-HP, 1 avenue Claude Vellefaux, 75010, Paris, France.
| |
Collapse
|
|
26
|
Lemiale V, Resche-Rigon M, Mokart D, Pène F, Rabbat A, Kouatchet A, Vincent F, Bruneel F, Nyunga M, Lebert C, Perez P, Meert AP, Benoit D, Chevret S, Azoulay E. Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study. Ann Intensive Care 2015; 5:28. [PMID: 26429355 PMCID: PMC4883632 DOI: 10.1186/s13613-015-0070-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 09/14/2015] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND In patients with hematological malignancies and acute respiratory failure (ARF), noninvasive ventilation was associated with a decreased mortality in older studies. However, mortality of intubated patients decreased in the last years. In this study, we assess outcomes in those patients according to the initial ventilation strategy. METHODS We performed a post hoc analysis of a prospective multicentre study of critically ill hematology patients, in 17 intensive care units in France and Belgium. Patients with hematological malignancies admitted for ARF in 2010 and 2011 and who were not intubated at admission were included in the study. A propensity score-based approach was used to assess the impact of NIV compared to oxygen only on hospital mortality. RESULTS Among 1011 patients admitted to ICU during the study period, 380 met inclusion criteria. Underlying diseases included lymphoid (n = 162, 42.6 %) or myeloid (n = 141, 37.1 %) diseases. ARF etiologies were pulmonary infections (n = 161, 43 %), malignant infiltration (n = 65, 17 %) or cardiac pulmonary edema (n = 40, 10 %). Mechanical ventilation was ultimately needed in 94 (24.7 %) patients, within 3 [2-5] days of ICU admission. Hospital mortality was 32 % (123 deaths). At ICU admission, 142 patients received first-line noninvasive ventilation (NIV), whereas 238 received oxygen only. Fifty-five patients in each group (NIV or oxygen only) were matched according the propensity score. NIV was not associated with decreased hospital mortality [OR 1.5 (0.62-3.65)]. CONCLUSIONS In hematology patients with acute respiratory failure, initial treatment with NIV did not improve survival compared to oxygen only. CLINICAL TRIAL gov number NCT 01172132.
Collapse
Affiliation(s)
- Virginie Lemiale
- AP-HP, Hôpital Saint-Louis, Medical ICU, 1 avenue Claude Vellefaux, 75010, Paris, France.
| | | | | | | | - Antoine Rabbat
- Respiratory Unit, Cochin Teaching Hospital, Paris, France.
| | | | | | | | | | | | | | | | | | - Sylvie Chevret
- Biostatistics Department, Saint Louis Teaching Hospital, Paris, France.
| | - Elie Azoulay
- AP-HP, Hôpital Saint-Louis, Medical ICU, 1 avenue Claude Vellefaux, 75010, Paris, France.
| |
Collapse
|
|
27
|
Ethical Challenges in Caring for Cancer Patients in the Intensive Care Unit: Advanced Care Pathways and Avoidance of Futility. CURRENT ANESTHESIOLOGY REPORTS 2015. [DOI: 10.1007/s40140-015-0116-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
|
28
|
[Mortality of hematology-oncology patients with neutropenia in intensivecare]. Med Klin Intensivmed Notfmed 2015; 111:84-91. [PMID: 25994843 DOI: 10.1007/s00063-015-0039-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Revised: 02/02/2015] [Accepted: 03/09/2015] [Indexed: 12/27/2022]
Abstract
BACKGROUND Febrile neutropenia remains one of the most common reasons for hospital admission of patients with underlying oncologic disease. These patients have an up to 10-fold increased risk of developing sepsis, which often leads to these patients being transferred to the intensive care unit (ICU). The survival of neutropenic patients with sepsis in particular has improved in recent years, due to advanced therapy in intensive care (surviving sepsis campaign); however few large international studies of neutropenic cancer patients in the ICU are available. METHODS In a retrospective study, 59 episodes of neutropenic cancer patients in the internal medicine ICU at the University Hospital of Cologne over a period of 2 years were analyzed. RESULTS Pneumonia with or without sepsis are the main admission diagnoses of neutropenic cancer patients in the ICU. The mortality rate of these patients is very high (50.8 %). Pneumonia and sepsis, stem cell transplantation, mechanical ventilation, and acute renal failure with or without dialysis are correlated with mortality. CONCLUSION Cancer patients should be admitted immediately to the ICU if they have signs of sepsis for early monitoring and treatment. Neutropenic patients have an increased risk for infectious complications and a risk for sepsis with higher mortality rates.
Collapse
|
|
29
|
Azoulay E, Pène F, Darmon M, Lengliné E, Benoit D, Soares M, Vincent F, Bruneel F, Perez P, Lemiale V, Mokart D. Managing critically Ill hematology patients: Time to think differently. Blood Rev 2015; 29:359-67. [PMID: 25998991 DOI: 10.1016/j.blre.2015.04.002] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Revised: 04/19/2015] [Accepted: 04/20/2015] [Indexed: 12/12/2022]
Abstract
The number of patients living with hematological malignancies (HMs) has increased steadily over time. This is the result of intensive and effective treatments that also increase the probability of infiltrative, infectious or toxic life threatening event. Over the last two decades, the number of patients with HMs admitted to the ICU increased and their mortality has dropped sharply. ICU patients with HMs require an extensive diagnostic workup and the optimal use of ICU treatments to identify the reason for ICU admission and the nature of the complication that explains organ dysfunctions. Mortality of ARDS or septic shock is up to 50%, respectively. In this review, the authors share their experience with managing critically ill patients with HMs. They discuss the main aspects of the diagnostic and therapeutic management of critically ill patients with HMs and argue that outcomes have improved over time and that many classic determinants of mortality have become irrelevant.
Collapse
Affiliation(s)
| | | | | | | | | | - Marcio Soares
- Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | | | | | | | | | | | | |
Collapse
|
|
30
|
Soares M, Azevedo LCP, Salluh JIF. Critical care use in patients with lung cancer. Chest 2015; 147:e56-e57. [PMID: 25644918 DOI: 10.1378/chest.14-2299] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Affiliation(s)
- Marcio Soares
- D'Or Institute for Research and Education, the Postgraduate Program, Hospital Sírio-Libanês.
| | - Luciano C P Azevedo
- Instituto Nacional de Câncer and the Research and Education Institute, Hospital Sírio-Libanês
| | - Jorge I F Salluh
- D'Or Institute for Research and Education, the Postgraduate Program, Hospital Sírio-Libanês
| |
Collapse
|